GlobeNewswire Inc.··NaProtara Posts $57.4M Annual Loss as TARA-002 Bladder Cancer Data Bolsters Pipeline
Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.
TARAfinancial resultsclinical trial